CVE-2026-32978: OpenClaw — HIGH

OpenClaw before 2026.3.11 contains an approval integrity vulnerability where system.run approvals fail to bind mutable file operands for certain script runners like tsx and jiti. Attackers can obtain approval for benign script commands, rewrite referenced scripts on disk, and execute modified code...

Full CISO analysis pending enrichment.

What systems are affected?

Package	Ecosystem	Vulnerable Range	Patched
OpenClaw	pip	—	No patch
4 dependents 37% patched ~3d to patch Full package profile →

Do you use OpenClaw? You're affected.

How severe is it?

CVSS 3.1

8.0 / 10

EPSS

N/A

Exploitation Status

No known exploitation

Sophistication

N/A

What is the attack surface?

AV Network

AC High

PR Low

UI Required

S Changed

C High

I High

A High

What should I do?

No patch available

Monitor for updates. Consider compensating controls or temporary mitigations.

Which compliance frameworks are affected?

Compliance analysis pending. Sign in for full compliance mapping when available.

Frequently Asked Questions

What is CVE-2026-32978?

OpenClaw before 2026.3.11 contains an approval integrity vulnerability where system.run approvals fail to bind mutable file operands for certain script runners like tsx and jiti. Attackers can obtain approval for benign script commands, rewrite referenced scripts on disk, and execute modified code under the approved run context.

Is CVE-2026-32978 actively exploited?

No confirmed active exploitation of CVE-2026-32978 has been reported, but organizations should still patch proactively.

How to fix CVE-2026-32978?

No patch is currently available. Monitor vendor advisories for updates.

What is the CVSS score for CVE-2026-32978?

CVE-2026-32978 has a CVSS v3.1 base score of 8.0 (HIGH).

What are the technical details?

Original Advisory

OpenClaw before 2026.3.11 contains an approval integrity vulnerability where system.run approvals fail to bind mutable file operands for certain script runners like tsx and jiti. Attackers can obtain approval for benign script commands, rewrite referenced scripts on disk, and execute modified code under the approved run context.

Weaknesses (CWE)

CWE-863 Incorrect Authorization

CWE-863 — Incorrect Authorization: The product performs an authorization check when an actor attempts to access a resource or perform an action, but it does not correctly perform the check.

[Architecture and Design] Divide the product into anonymous, normal, privileged, and administrative areas. Reduce the attack surface by carefully mapping roles with data and functionality. Use role-based access control (RBAC) [REF-229] to enforce the roles at the appropriate boundaries. Note that this approach may not protect against horizontal authorization, i.e., it will not protect a user from attacking others with the same role.
[Architecture and Design] Ensure that access control checks are performed related to the business logic. These checks may be different than the access control checks that are applied to more generic resources such as files, connections, processes, memory, and database records. For example, a database may restrict access for medical records to a specific database user, but each record might only be intended to be accessible to the patient and the patient's doctor [REF-7].

Source: MITRE CWE corpus.